Dianthus Therapeutics Inc
NASDAQ:DNTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Dianthus Therapeutics Inc
NASDAQ:DNTH
|
US |
|
Interlink Electronics Inc
NASDAQ:LINK
|
US |
Intrinsic Value
The intrinsic value of Dianthus Therapeutics Inc (DNTH) under the Base Case is 15.256 USD per share.
Compared with the current market price of 74.965 USD, the stock appears
Overvalued by 80% .
The intrinsic value is calculated using the DCF method. Operating margin recovers from -8739% last year to 1% by 2031. If operating margin stayed at its five-year average of -2416%, the estimate would be about $19. The value of the years after 2031 is tied to revenue, so margins count only until then.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Dianthus Therapeutics Does
Dianthus Therapeutics is a biotechnology company that develops antibody medicines for serious autoimmune and complement-driven diseases. Its main job is to discover and test drug candidates that can block parts of the immune system that cause harmful inflammation and tissue damage. The company does not sell a broad range of commercial products; it is focused on advancing a small pipeline of experimental therapies through clinical development.
- Headquarters
- United States of America US
- Employees
- 92
- IPO date
- Jun 21, 2018
Revenue & Expenses Breakdown
Dianthus Therapeutics Inc
Earnings Waterfall
Dianthus Therapeutics Inc
The intrinsic value for Dianthus Therapeutics Inc (DNTH) under the Base Case is 15.256 USD.
Compared with the current market price of 74.965 USD, the stock appears Overvalued by 80% .